Search Within

Nicole Alexa Schreiber

Formats
  1. Meeting Abstract (20)
  2. Journal Article (8)
Groups
  1. Department of Medicine (28)
  2. Genitourinary Oncology Service (28)
  3. Solid Tumor Oncology Division (28)
  4. Department of Pathology and Laboratory Medicine (20)
  5. Epidemiology and Biostatistics (9)
  6. Biostatistics Service (7)

More Groups

People
  1. Howard Scher (27)
  2. Martin Fleisher (17)
  3. Brigit McLaughlin (11)
  4. Daniel Danila (11)
  5. Glenn Heller (7)
  6. Richard Bambury (6)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2019 (1)
  4. 2018 (5)
  5. 2017 (5)
  6. 2016 (6)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Cancer Research (3)
  3. JAMA Oncology (3)
  4. Annals of Oncology (2)
  5. Cancer Prevention Research (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. American Association for Cancer Research (5)
  3. American Medical Association (3)
  4. Elsevier Science, Inc. (2)
  5. Oxford University Press (2)
  6. Elsevier Inc. (1)

More Publishers

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
    Meeting Abstract

    Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Jendrisak, A.; Wang, Y.; Lee, J.; Greene, S.; Krupa, R.; Lu, D.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy
    Meeting Abstract

    Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Lu, D.; Schreiber, N. A.; Louw, J.; Graf, R. P.; Vargas, H. A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; more...
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients
    Journal Article

    Danila, D. C.; Samoila, A.; Patel, C.; Schreiber, N.; Herkal, A.; Anand, A.; Bastos, D.; Heller, G.; Fleisher, M.; Scher, H. I.
    The Cancer Journal (2016)

    Fulltext@MSK | Save
  • Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients
    Meeting Abstract

    Scher, H. I.; Graf, R.; Louw, J.; Jendrisak, A.; Johnson, A.; Greene, S.; Rodriguez, A.; Schreiber, N. A.; McLaughlin, B.; Dugan, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer
    Journal Article

    Beltran, H.; Jendrisak, A.; Landers, M.; Mosquera, J. M.; Kossai, M.; Louw, J.; Krupa, R.; Graf, R. P.; Schreiber, N. A.; Nanus, D. M.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Scher, H. I.; Szafer-Glusman, E.; Herkal, A.; Suttmann, R.; Fleisher, M.; Schreiber, N. A.; Curtis, K.; Gilbert, H.; Maslyar, D.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save